The test consists of a small device that requires only 10 microlitres of patient serum or
plasma, or 20 microlitres of whole blood, to be loaded into a receptacle, alongside an
included buffer, which then mixes with viral S protein fragments and migrates along
the device to an area of immobilized capture antibodies. If virus specific IgG or IgM is
present, conjugates are formed, which show up as a distinctive red band on the
device.
Clinical validation studies have been completed by the manufacturer according to
Administrative Measures for Registration of In-vitro Diagnostic Reagents.
They will have to test it on infected people here, this is a huge gamble, it sounds very much like the shonky kits that screwed over Spain to me
- Forums
- ASX - By Stock
- Ann: Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
The test consists of a small device that requires only 10...
-
- There are more pages in this discussion • 1,236 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable